Jessica Hudson, MD, MPHS, general surgery resident at Washington University School of Medicine in St. Louis, has been honored with the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) Merit Award. Dr. Hudson will receive the Conquer Cancer Foundation Merit Award and present her winning abstract at the ASCO annual meeting in June. This award aims to invest in the future of cancer care by recognizing outstanding oncology trainees and rewarding excellence and innovation in scientific oncologic research.
In the abstract, The role of adjuvant chemotherapy in stage IB non-small cell lung cancer: A decision, effectiveness, and cost-effectiveness analysis, Dr. Hudson and colleagues examined patients with stage IB lung cancer, which includes larger tumors within the lung that have not yet spread to other sites. They found that the addition of chemotherapy after surgical resection in these lung cancer patients extended the patient’s life and did so in a cost-efficient manner for the most commonly used chemotherapy medications. Findings from Dr. Hudson and colleagues could provide future patients with a new treatment option, as adjuvant chemotherapy use for stage IB lung cancer patients is still debated among physicians. With adjuvant chemotherapy, physicians could now treat stage IB lung cancer with more than just surgery. It is possible that adjuvant chemotherapy would improve patient survival and outcomes, in addition to providing patients other treatment possibilities.
Dr. Hudson aspires to become a thoracic surgeon with a strong clinical practice balanced by research in comparative effectiveness. She credits the success of this project to the Washington University Master in Population Health Science (MPHS) program, stating that it gave her the skills necessary to perform impactful clinical research that is on the leading edge of research techniques and enriched the work through insight from world-renowned faculty. “Population health studies allow residents and fellows to address the welfare of the general population as well as the needs of individual patients, providing invaluable training that has the potential to transform these research opportunities into career-launching experiences,” said Dr. Hudson.
About the Merit Award Program
The merit award program was established in 1995 to recognize high quality abstracts submitted by fellows and residents and encourage attendance at the Annual Meeting. Recipients receive complimentary meeting registration and a $1,000 stipend to assist with expenses associated with attending the 2017 ASCO Annual Meeting. The number of merit awards varies each year as awards are dependent on funding. ASCO announced the 2017 Conquer Cancer Foundation Merit Award winners May 17. The 2017 Conquer Cancer Foundation of ASCO Merit Awards are supported by Amgen; AstraZeneca; the Bradley Stuart Beller Endowment Fund; Ipsen Biopharmaceuticals Inc.; Janssen Oncology; Kidney Cancer Association; Lilly; Merck & Co., Inc.; the James B. Nachman Pediatric Oncology Fund; Novartis Oncology; and Takeda Oncology. More information can be found online.